Jump to main content
Jump to site search

Issue 23, 2012
Previous Article Next Article

Rapidly quantifying drug sensitivity of dispersed and clumped breast cancer cells by mass profiling

Author affiliations

Abstract

Live cell mass profiling is a promising new approach for rapidly quantifying responses to therapeutic agents through picogram-scale changes in cell mass over time. A significant barrier in mass profiling is the inability of existing methods to handle pleomorphic cellular clusters and clumps, which are more commonly present in patient-derived samples or tissue cultures than are isolated single cells. Here we demonstrate automated Live Cell Interferometry (LCI) as a rapid and accurate quantifier of the sensitivity of single cell and colony-forming human breast cancer cell lines to the HER2-directed monoclonal antibody, trastuzumab (Herceptin). The relative sensitivities of small samples (<500 cells) of four breast cancer cell lines were determined tens-to-hundreds of times faster than is possible with traditional proliferation assays. These LCI advances in clustered sample assessment and speed open up the possibility for therapeutic response testing of patient-derived solid tumor samples, which are viable only for short periods ex vivo and likely to be in the form of cell aggregates and clusters.

Graphical abstract: Rapidly quantifying drug sensitivity of dispersed and clumped breast cancer cells by mass profiling

Back to tab navigation

Supplementary files

Publication details

The article was received on 02 Aug 2012, accepted on 02 Oct 2012 and first published on 11 Oct 2012


Article type: Communication
DOI: 10.1039/C2AN36058F
Citation: Analyst, 2012,137, 5495-5498
  •   Request permissions

    Rapidly quantifying drug sensitivity of dispersed and clumped breast cancer cells by mass profiling

    J. Chun, T. A. Zangle, T. Kolarova, R. S. Finn, M. A. Teitell and J. Reed, Analyst, 2012, 137, 5495
    DOI: 10.1039/C2AN36058F

Search articles by author

Spotlight

Advertisements